Company: DMAAR
Filing Date: 2025-02-25
Form Type: 8-K
Source: 0001213900-25-016702
Chunk: 0

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-02-25
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01. Other Events.

As previously disclosed
on a Current Report on Form 8-K dated January 27, 2025, Drugs Made In America Acquisition Corp. (the “ Company”) consummated
its initial public offering (the “ IPO”) of 20,000,000 units (the “ Units”). Each Unit consists of one ordinary
share (“ Ordinary Share”) and one right to receive one-eighth (1/8) of one Ordinary Share upon the consummation of an initial
business combination. The Units were sold at a price of $10.00 per Unit, generating aggregate gross proceeds to the Company of $200,000,000.
The Company granted the underwriters a 45-day option to purchase up to 3,000,000 additional Units to cover over-allotments, if any.

As also previously disclosed
in the Current Report, simultaneously with the closing of the IPO, the Company consummated a private placement (the “ Private Placement”)
in which Drugs Made In America Acquisition LLC, the Company’s sponsor, purchased 400,000 units (the “ Private Units”)
at a price of $10.00 per unit, for $4,000,000, of which $1,100,000 has not yet been received and is accounted for as a subscription receivable
in the attached balance sheet.

Subsequently, on February 13, 2025, the underwriters
exercised the over-allotment option in full, and the closing of the issuance and sale of the additional Units (the “ Over-Allotment
Option Units”) occurred on February 18, 2025. The total aggregate issuance by the Company of 3,000,000 Over-Allotment Option Units
at a price of $10.00 per unit resulted in total gross proceeds of $30,000,000. On February 18, 2025, simultaneously with the sale of the
Over-Allotment Option Units, the Company consummated the private sale of an additional 30,000 Private Units, generating gross proceeds
of $300,000. The Private Units were issued pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, as the transactions
did not involve a public offering.

A total of $ 231,150,000 of the net proceeds from
the sale of Units in the IPO (including the Over-Allotment Option Units) and